The treatment of acromegaly with long-acting octreotide: the effective control of disease activity and decrease of the tumour volume
https://doi.org/10.14341/probl20125843-7
Abstract
References
1. Молитвословова Н.Н. Акромегалия: современные достижения в диагностике и лечении. Пробл эндокринол 2011; 1: 46-57.
2. Пронин В.С., Агаджанян С.Э., Гитель Е.П., Молитвословова Н.Н., Марова Е.И., Алексеева Т.М. Особенности клинического течения акромегалии и лечебной тактики в зависимости от возраста пациентов при начале заболевания. Пробл эндокринол 2006; 52: 3: 33-40.
3. Melmed S., Colao A., Barkan A., Melmed S., Colao A., Barkan A., Molitch M., Grossman A.B., Kleinberg D., Clemmons D., Chanson P., Laws E., Schlechte J., Vance M.L., Ho K., Giustina A. Guidelines for Acromegaly Management: An Update. J Clin Endocrinol Metab 2009; 94: 5: 1509-1517.
4. Holdway I.M., Bolland M.J., Gamble G.D. A metaanalysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008; 159: 89-95.
5. Holdway I.M., Rajasoorya R.C., Gamble G.D. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89: 2: 667-674.
6. Kauppinen-Makelin R., Sane T., Reunanen A., Valimaki M.J., Niskanen L., Markkanen H., Loyttyniemi E., Ebeling T., Jaatinen P., Laine H. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005; 90: 4081-4086.
7. Melmed S., Casanueva F., Cavagnini F., Chanson P., Frohman I., Grossman A., Ho K., Kleinberg D., Lamberts S., Laws E., Lombardi G., Vance M.L., Von Werder K., Wass J., Giustina A. Guidelines for Acromegaly Management. J Clin Endocrinol Metab 2002; 87: 9: 4054-4058.
8. Colao A., Pivonello R., Auriemma R.S., Briganti F., Galdiero M., Tortora F., Caranci F., Cirillo S., Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006; 91: 6: 2112-2118.
9. Melmed S., Casanueva F.F., Cavagnini F., Chanson P., Frohman L. A., Gaillard R., Ghigo E., Ho K., Jaquet P., Kleinberg D., Lamberts S., Laws E., Lombardi G., Sheppard M.C., Thorner M., Vance M.L., Wass J., Giustina A. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005; 153: 737-740.
10. Besser G.M., Burman P., Daly A.F. Predictors and rates of treatment resistant tumor growth in acromegaly. Eur J Endocrinol 2005; 153: 2: 187-193.
11. Di Chiro G., Nelson K.B. The volume of the sella turcica. Am J Radiol 1962; 87: 989-1008.
12. Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocrinol Rev 2004; 25: 102-152.
13. Bates A.S., Van't Hoff W., Jones J.M. Clayton R.N. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86: 293-299.
14. Colao A., Auriemma R.S., Lombardi G., Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocrinol Rev 2011; 32: 2: 247-271.
15. Colao A., Pivonello R., Rosato F., Tita P., De Menis E., Barreca A., Ferrara R., Mainini F., Arosio M., Lombardi G. First-line octreotide-LAR therapy induces tumor shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxford) 2006; 64: 342-351.
Review
For citations:
Dogadin S.A., Dudina M.A., Lobyntseva L.A. The treatment of acromegaly with long-acting octreotide: the effective control of disease activity and decrease of the tumour volume. Problems of Endocrinology. 2012;58(4):3-7. https://doi.org/10.14341/probl20125843-7
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
